Synchrony

Synchrony is an early stage pre-seed start-up that is aimed at development of a novel anticancer treatment paradigm. Our first target, colorectal cancer (CRC) is the 2nd most common cause of cancer death in the UK. 41,700 new cases in UK annually and an average of 43% mortality demonstrate a massive unmet patient need. We aim to establish a novel framework technology that can be expanded into other cancer types and allow Big Pharma to repurpose their compounds.